Immix Biopharma, Inc.
IMMX· Nasdaq
Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001493152-26-051383
On November 12, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for its quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$13.93M | -$7.59M | -$7.15M | -$4.28M |
| EPS Diluted | -$0.19 | -$0.24 | -$0.24 |
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR
| -$0.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.